Dr. Hill on Managing CRS in Patients Treated With CAR T-Cell Therapy

Video

Brian T. Hill, MD, PhD, discusses the management of cytokine release syndrome in patients with hematologic malignancies who are treated with CAR T-cell therapy.

Brian T. Hill, MD, PhD, director of the Lymphoid Malignancies Program and staff physician, Taussig Cancer Institute, and assistant professor, Hematology and Oncology, Cleveland Clinic, discusses the management of cytokine release syndrome (CRS) in patients with hematologic malignancies who are treated with CAR T-cell therapy.

CRS, or cytokine storm, is caused by a high activation level of immune effector cells that are mediated by cytokines, such as interleukin-6 (IL-6), Hill says. Typically, CRS occurs within the first 2 to 4 days following administration of CAR T-cell therapy.

The cytokines induce a sepsis-like physiological response that may include fever, tachycardia, hypoxia, or hypotension, says Hill. Moreover, these adverse effects typically require the patient to be treated in the intensive care unit.

Management strategies for CRS include the administration of tocilizumab (Actemra), which is an anti­­–IL-6 monoclonal antibody, Hill explains.

However, treatment should take place at an expert-level facility that is experienced in managing CRS, concludes Hill.

Recent Videos
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
© 2024 MJH Life Sciences

All rights reserved.